Enhanced antitumour activity of cyclopendadienyl-substituted metallocene dihalides in human breast and colon cancer cells

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 3227-3231

  Stachtea, Xanthi ^a   Karamanos, Nikos ^a   Klouras, Nikolaos ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Breast cancer; Colon cancer; Metallocene dihalides; Titanocene dichloride

Indexed keywords

METAL COMPLEX; METALLOCENE DIHALIDE; ORGANOMETALLIC COMPOUND; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BREAST NEOPLASMS; CELL PROLIFERATION; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; ORGANOMETALLIC COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 68649117934     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Sab G, Seeber S, Thiel E and Berdel W: Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumours. Clin Cancer Res 4: 2701-2708, 1998. (Pubitemid 28523495)
2. Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Eliopoulos A, Hale K, Baumgart J, Sass G and Kerr D J: Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol 16: 2761-2769, 1998. (Pubitemid 28363042)
3. Köpf-Maier P: Antitumour bis(cyclopentadienyl)metal complexes. In: Metal Complexes in Cancer Chemotherapy. Keppler BK (ed.). VCH Verlagsgesellschaft, Weinheim, pp. 259-296, 1993.
4. Lümmen G, Sperling H, Luboldt H, Otto T and Rübben H: Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42: 415-417, 1998. (Pubitemid 28430373)
5. Köpf-Maier P and Köpf H: Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes-early transition metal antitumour drugs. In: Metal Compounds in Cancer Therapy. Flicker SP (ed.). Chapman and Hall, London, pp. 109-146, 1994.
6. Köpf-Maier P, Kahl W, Klouras N, Hermann G and Köpf H: Tumorhemmung durch Metallocene: Ringsubstituierte und ringüberbrückte Titanocen-dichloride. Eur J Med Chem 16: 275-281, 1981.
7. Wilkinson G and Birmingham JM: Bis-cyclopentadienyl compounds of Ti, Zr, V, Nb, and Ta. J Am Chem Soc 76: 4281-4284, 1954.
8. 2. Z Anorg allg Chem 622: 898-902, 1996.
9. 2-type complex. J Am Chem Soc 97: 6422-6432, 1975.
10. Köpf H and Klouras N: Neue 1,1′-ringsubstituierte Metallocen-dihalogenide. Chem Scripta 19: 122-123, 1982.
11. 2. Monatsh Chem 122: 551-556, 1991.
12. Moise C, Leblanc JC and Tirouflet J: Asymmetric titanium(IV) metal. First example of a resolved titanocene derivative. J Am Chem Soc 97: 6272-6274, 1975.
13. Caruso F and Rossi M: Antitumour titanium compounds. Mini Rev Med Chem 4: 49-60, 2004.
14. Christodoulou CV, Eliopoulos AG, Young LS, Hodgkins L, Ferry DR and Kerr DJ: Antiproliferative activity and mechanism of action of titanocene dichloride. Br J Cancer 77: 2088-2097, 1998. (Pubitemid 28263927)
15. Stahtea XN, Roussidis AE, Kanakis I, Tzanakakis GN, Chalkiadakis G, Mavroudis D, Kletsas D and Karamanos NK: Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer 121(12): 2808-2814, 2007. (Pubitemid 350136431)
16. 2 and implications for anticancer activity. Metal-Based Drugs 5: 207-215, 1998. (Pubitemid 28448690)
17. Clarke MJ, Zhu F and Frasca DR: Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99(9): 2511-2534, 1999.
18. Gao LM, Hernández R, Matta J and Meléndez E: Synthesis, Ti(IV) intake by apotransferrin and cytotoxic properties of functionalized titanocene dichlorides. J Biol Inorg Che 12(7):959-967, 2007.
19. Hernández R, Lamboy J, Gao LM, Matta J, Román FR and Meléndez E: Structure-activity studies of Ti(IV) complexes: aqueous stability and cytotoxic properties in colon cancer HT-29 cells. J Biol Inorg Chem 13: 685-692, 2008.
20. Mokdsi G and Harding MM: Inhibition of human topoisomerase II by the antitumour metallocenes. J Organomet Chem 565: 29-35, 1998.
21. Yasuda H, Yasuhara T, Yamamoto H, Takei K and Nakamura A: Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Chem Express 3: 375-378, 1998.
22. Kroger N, Kleeberg UR, Mross K, Edler L, Saß G and Hossfeld DK: Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie 23: 60-62, 2000. (Pubitemid 30154851)
23. Waern JB, Harris HH, Zhonghou BL, Harding MM and Dillon CT: Intracellular mapping of the distribution of metals derived from the antitumour metallocenes. J Biol Inorg Chem 10: 443-452, 2005.
24. Vyhlidal C, Li X and Safe S: Estrogen regulation of transferrin gene expression in MCF-7 human breast cancer cells. J Mol Endocrinol 29: 305-317, 2002. (Pubitemid 36032670)
25. Mokdsi G and Harding MM: Inhibition of human topoisomerase II by the antitumour metallocenes. J Inorg Chem 83: 205-209, 2001. (Pubitemid 32106991)
26. IV uptake and release by transferrin. J Chem Soc Dalton Trans 1: 7-9, 2000.